Neurologic indications for therapeutic plasma exchange: 2011 update

Gwathmey, Kelly; Balogun, Rasheed A.; Burns, Ted M.

doi:10.1002/jca.21219

Cited by 53 publications

(25 citation statements)

References 119 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Once a diagnosis of NMO is made, the therapeutic goals for these patients include quickly preventing further production of the offending antibody with immunosuppressive therapy. In patients who do not respond to pharmacotherapy, therapeutic plasma exchange (TPE) may be beneficial in both the acute setting and in the preventative setting [8,[14][15][16][17][18][19][20][21][22][23]. The benefits are likely through removal of circulating pathogenic immune or inflammatory substances [24].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic plasma exchange in neuromyelitis optica: A case series

Morgan

Zantek

Carpenter

2013

J of Clinical Apheresis

View full text Add to dashboard Cite

Neuromyelitis optica (NMO) is a relapsing inflammatory disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The clinical hallmark of the disease is a step-wise deterioration of visual and spinal cord function. This study reviews patients with steroid resistant relapsing NMO presenting for therapeutic plasma exchange (TPE) at our institution from December 2005 to December 2012. A total of five patients were treated with single volume TPE. Both subjective and objective clinical response to TPE was estimated by three different sources (the patient, a Transfusion Medicine physician, and the treating Neurologist) with the patient and Transfusion Medicine physician's final assessment of response made at the time of the last TPE in the series and the treating neurologist's assessment of response made at the time of the next neurological exam after the last TPE. A total of 17 TPE series were performed with the average course of therapy being three series (ranged 1-5) with five TPE (ranged 3-7) per series. All patients demonstrated improvement with each series of TPE and all procedures were well tolerated with only transient and well-described reactions all of which were successfully resolved with minor or no sequelae.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic plasma exchange in neuromyelitis optica: A case series

Morgan

Zantek

Carpenter

2013

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…Plazmafereza może być również przydatnym elementem leczenia wielu chorób (wskazania klasy IB) o podłożu neurologicznym, hematologicznym czy nefrologicznym, takich jak przewlekła zapalna demielinizacyjna poliradikuloneuropatia, krioglobulinemia, zespół nadlepkości, popaciorkowcowy dziecięcy zespół neuropsychiatryczny (PANDAS, pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections), odrzucenie przeszczepu nerki, konflikt serologiczny na tle niezgodności czynnika Rh [3,4,5,6]. W wielu innych jednostkach chorobowych określenie przydatności leczniczej wymiany osocza pozostaje przedmiotem badań.…”

unclassified

Powikłania u chorych leczonych metodą plazmaferezy na oddziale intensywnej terapii

Szczeklik¹,

Wawrzycka²,

Włudarczyk³

et al. 2013

Anaesthesiol Intensive Ther

View full text Add to dashboard Cite

Background. Plasmapheresis is one of the methods of extracorporeal blood purification involving the removal of inflammatory mediators and antibodies. The procedure is used in a variety of ailments, including autoimmune diseases. The aim of the present study was to analyse the incidence of plasmapheresis-related complications in patients treated in the intensive care unit (ICU). Methods. The analysis involved 370 plasmapheresis procedures in 54 patients. The data were collected from patients` medical records, including procedure protocols. Results. The most common diseases treated with plasmapheresis included: myasthenia gravis (33.3%), Guillain-Barré syndrome (14%), Lyell's syndrome (9.3%), systemic lupus erythematosus (7.4%), and thrombotic thromcytopenic purpura (7.4%). The adverse side effects observed most frequently during plasma filtration were decreases in arterial blood pressure (8.4% of all procedures), arrhythmias (3.5%), sensations of cold with temporarily elevated temperature and paresthesias (1.1%, each). In most cases, the symptoms were mild and transient. Severe and life-threatening episodes, i.e. shock, drops in arterial blood pressure requiring catecholamines administration, persistent arrhythmias and haemolysis, developed in 2.16% of procedures. Conclusions. Plasmapheresis can be considered a relatively safe method of treatment of ICU patients. Continuous observation and proper monitoring of patients provided by highly trained medical personnel are essential for its safety.

show abstract

“…There are few case reports that used DFPP (2,3) for this disease. It is said that if the risk to fall into respiratory failure is serious, plasmapheresis should start (4). We judged that the effect of first steroidpulse therapy was poor, and substituted an apheresis regimen in combination with steroid-pulse therapy early, and our case succeeded.Therefore, it was essential to recognize and report the utility of DFPP in our patient.…”

mentioning

confidence: 78%